Literature DB >> 2309826

Pharmacokinetics of ritodrine administered intravenously: recommendations for changes in the current regimen.

S N Caritis1, R Venkataramanan, M J Darby, J P Chiao, M Krew.   

Abstract

We define the pharmacokinetics of ritodrine in 13 pregnant women who received the drug intravenously. With constant infusion of 50 micrograms/minute, steady state ritodrine concentrations reached 28 +/- 11 ng/ml (SD) with a range of 15 to 45 ng/ml. This wide variation is a result of differences in plasma clearance, which ranged from 1.0 to 3.3 L/min, mean 1.94 +/- 0.71 L/min. The apparent volume of distribution was 6.95 +/- 3.54 L/kg, indicating that ritodrine is extensively bound to extravascular tissue. When an infusion of ritodrine is stopped, plasma concentrations fall rapidly initially with a distribution half-life of 5.9 +/- 6.0 minutes. After the initial rapid fall, plasma concentrations decrease more slowly with a mean disposition half-life of 156 +/- 51 minutes. On the basis of the pharmacokinetic parameters defined, we recommend that the current infusion regimen for ritodrine be changed. The infusion rate of ritodrine should start at 50 micrograms/minute rather than 100 micrograms/minute. The maximal infusion rate of 350 micrograms/minute should be increased and once labor is inhibited, the infusion rate should be reduced.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2309826     DOI: 10.1016/0002-9378(90)90401-r

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  5 in total

Review 1.  Pharmacokinetics of tocolytic agents.

Authors:  Vassilis Tsatsaris; Dominique Cabrol; Bruno Carbonne
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

2.  Pharmacokinetics of 17-hydroxyprogesterone caproate in multifetal gestation.

Authors:  Steve N Caritis; Shringi Sharma; Raman Venkataramanan; Dwight J Rouse; Alan M Peaceman; Anthony Sciscione; Catherine Y Spong; Michael W Varner; Fergal D Malone; Jay D Iams; Brian M Mercer; John M Thorp; Yoram Sorokin; Marshall Carpenter; Julie Lo; Susan Ramin; Margaret Harper
Journal:  Am J Obstet Gynecol       Date:  2011-03-22       Impact factor: 8.661

3.  Pharmacokinetics of ritodrine diastereomers in patients pregnant with singletons and twins.

Authors:  A Konda; T Ito; H Yoshida; T Toda; T Hayakawa; N Inotsume
Journal:  Eur J Clin Pharmacol       Date:  2009-05-27       Impact factor: 2.953

4.  Ritodrine pharmacokinetics in twin pregnancy patients.

Authors:  A Konda; A Nodai; M Soma; Y Koga; H Yoshida; T Toda; T Hayakawa; N Inotsume
Journal:  Eur J Clin Pharmacol       Date:  2007-12-18       Impact factor: 2.953

5.  Rebound hyperkalemia after cessation of ritodrine in a parturient undergoing cesarean section.

Authors:  Daiki Takekawa; Kei Jinushi; Masato Kitayama; Kazuyoshi Hirota
Journal:  JA Clin Rep       Date:  2017-01-05
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.